You are here:

Archived: anidulafungin (Ecalta)

Advice

Following a full submission

anidulafungin (Ecalta) is not recommended for use within NHS Scotland for the treatment of invasive candidiasis in adult non-neutropenic patients.

Anidulafungin has been shown to be at least as effective as an alternative antifungal in a study of patients of whom the majority had candidaemia. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: anidulafungin (Ecalta)
SMC Drug ID: 465/08
Manufacturer: Pfizer Ltd
Indication: For the treatment of invasive candidiasis in adult non-neutropenic patients
BNF Category:
Sub Category: 5.2 Antifungal Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 June 2008

Current Advice

Resubmission 10 November 2008

Back